Leah Burns
About
Leah Burns is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Physiology.
According to data from OpenAlex, Leah Burns has authored 33 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 8 papers in Economics and Econometrics and 6 papers in Physiology. Recurrent topics in Leah Burns's work include Dementia and Cognitive Impairment Research (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Alzheimer's disease research and treatments (5 papers). Leah Burns is often cited by papers focused on Dementia and Cognitive Impairment Research (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Alzheimer's disease research and treatments (5 papers). Leah Burns collaborates with scholars based in United States, Sweden and Germany. Leah Burns's co-authors include Fatema Nader, Zobair M. Younossi, Arian Afendy, Ying Qiu, Natsu Fukui, Pegah Golabi, Manirath Srishord, Leyla de Avila, James M. Paik and Ying Qiu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.
In The Last Decade
Leah Burns
29 papers receiving 2.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Leah Burns United States | 12 | 1.5k | 844 | 498 | 334 | 311 | 33 | 2.1k | ||
| Mark Jaros United States | 17 | 723 0.5× | 567 0.7× | 293 0.6× | 168 0.5× | 725 2.3× | 50 | 3.1k | ||
| Jonathan Hazlehurst United Kingdom | 19 | 2.2k 1.5× | 1.8k 2.1× | 555 1.1× | 464 1.4× | 654 2.1× | 43 | 3.1k | ||
| Silvia Pinach Italy | 24 | 412 0.3× | 549 0.7× | 123 0.2× | 222 0.7× | 620 2.0× | 44 | 1.9k | ||
| You‐Bin Lee South Korea | 23 | 459 0.3× | 628 0.7× | 115 0.2× | 407 1.2× | 189 0.6× | 104 | 1.5k | ||
| Robert Bergholm Finland | 27 | 2.2k 1.5× | 1.5k 1.7× | 444 0.9× | 977 2.9× | 770 2.5× | 34 | 4.0k | ||
| Guido Lattuada Italy | 24 | 1.2k 0.8× | 828 1.0× | 238 0.5× | 721 2.2× | 392 1.3× | 52 | 2.5k | ||
| Maria Perticone Italy | 29 | 536 0.4× | 723 0.9× | 119 0.2× | 503 1.5× | 443 1.4× | 132 | 2.5k | ||
| Miguel A. Serra Spain | 28 | 1.6k 1.1× | 111 0.1× | 1.9k 3.9× | 228 0.7× | 392 1.3× | 61 | 2.8k | ||
| Thomas Marjot United Kingdom | 21 | 1.0k 0.7× | 477 0.6× | 353 0.7× | 243 0.7× | 249 0.8× | 49 | 1.8k | ||
| Christos Tikellis Australia | 25 | 402 0.3× | 1.2k 1.4× | 160 0.3× | 339 1.0× | 1.1k 3.5× | 30 | 3.7k |
Countries citing papers authored by Leah Burns
Since
Specialization
Citations
This map shows the geographic impact of Leah Burns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leah Burns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leah Burns more than expected).
Fields of papers citing papers by Leah Burns
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Leah Burns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leah Burns. The network helps show where Leah Burns may publish in the future.
Co-authorship network of co-authors of Leah Burns
This figure shows the co-authorship network connecting the top 25 collaborators of Leah Burns. A scholar is included among the top collaborators of Leah Burns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leah Burns. Leah Burns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Burns, Leah, et al.. (2023). Real-world evidence for regulatory decision-making: updated guidance from around the world. Frontiers in Medicine. 10. 1236462–1236462.
2.
Swaminathan, Aparna, Laurie D. Snyder, Hwanhee Hong, et al.. (2023). External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. American Journal of Respiratory and Critical Care Medicine. 208(5). 579–588.
3.
Burns, Leah, et al.. (2022). Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies. Advances in Therapy. 39(10). 4772–4778.
4.
Burns, Leah, et al.. (2022). Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World. Clinical Therapeutics. 44(3). 420–437.
5.
Burns, Leah, Yuqing Gong, Kaining Zhi, et al.. (2020). An update on drug–drug interactions between antiretroviral therapies and drugs of abuse in HIV systems. Expert Opinion on Drug Metabolism & Toxicology. 16(11). 1005–1018.
6.
Younossi, Zobair M., Pegah Golabi, Leyla de Avila, et al.. (2019). The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology. 71(4). 793–801.
7.
Younossi, Zobair M., Radhika P. Tampi, Andrei Racila, et al.. (2019). Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. Diabetes Care. 43(2). 283–289.
8.
Weycker, Derek, Xiaoyan Li, Gail Wygant, et al.. (2018). SAFETY AND EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN THE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM. Journal of the American College of Cardiology. 71(11). A1953–A1953.
9.
Weycker, Derek, Xiaoyan Li, Gail Wygant, et al.. (2018). Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. Thrombosis and Haemostasis. 118(11). 1951–1961.
10.
Price, Karen, et al.. (2017). FRI0499 Real-world study on the patterns and cost of treatment failure in patients with psoriatic arthritis using us claims data. Annals of the Rheumatic Diseases. 76. 677–677.
11.
Lip, Gregory Y.H., Allison Keshishian, Shital Kamble, et al.. (2016). REAL WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON APIXABAN, WARFARIN, DABIGATRAN OR RIVAROXABAN: A 1:1 PROPENSITY-SCORE MATCHED ANALYSIS. Journal of the American College of Cardiology. 67(13). 882–882.
12.
Pan, Xianying, Shital Kamble, Leah Burns, et al.. (2016). WHAT DO REAL WORLD DATA SAY ABOUT SAFETY AND RESOURCE USE OF ORAL ANTAGONISTS? EARLY ANALYSIS OF NEWLY ANTICOAGULATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS USING EITHER APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN. Journal of the American College of Cardiology. 67(13). 894–894.
13.
Zimmerman, Molly E., Mindy J. Katz, Cuiling Wang, et al.. (2015). Comparison of “Word” vs. “Picture” version of the Free and Cued Selective Reminding Test (FCSRT) in older adults. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 1(1). 94–100.
14.
Burns, Leah, Lucinda Orsini, & Gilbert L’Italien. (2013). Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use. Value in Health. 16(6). S16–S19.
15.
Yaffe, Kristine, Michael Tocco, Ronald C. Petersen, et al.. (2012). The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials. Alzheimer s & Dementia. 8(3). 237–242.
16.
Rossum, Ineke A. van, Stephanie J. B. Vos, Leah Burns, et al.. (2012). Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology. 79(17). 1809–1816.
17.
Portelius, Erik, Kaj Blennow, Ulf Andréasson, et al.. (2011). O2‐01‐06: The Gamma Secretase Inhibitor, BMS‐708163 Increases Alpha Secretase Abeta Peptide Cleavage Fragments and Decreases the Gamma Secretase Abeta Peptide 1‐34 Fragment in Cerebrospinal Fluid. Alzheimer s & Dementia. 7(4S_Part_8).
18.
Vos, Stephanie J. B., Hilkka Soininen, Pieter Jelle Visser, et al.. (2011). O1‐06‐03: CSF and MRI biomarkers as predictors for Alzheimer's‐type dementia in subjects with mild cognitive impairment. Alzheimer s & Dementia. 7(4S_Part_3).
19.
Rueckert, Daniel, Ronald A. van Schijndel, Frans R.J. Verhey, et al.. (2011). P1‐072: Comparison of measurements of medial temporal lobe atrophy in the prediction of Alzheimer's Disease in subjects with MCI. Alzheimer s & Dementia. 7(4S_Part_4).
20.
Donato, B.M.K., et al.. (2010). Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: A descriptive report. Clinical Therapeutics. 32(3). 546–554.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark Jaros Breakdown of academic impact, for papers by Jonathan Hazlehurst Breakdown of academic impact, for papers by Silvia Pinach Breakdown of academic impact, for papers by You‐Bin Lee Breakdown of academic impact, for papers by Robert Bergholm Breakdown of academic impact, for papers by Guido Lattuada Breakdown of academic impact, for papers by Maria Perticone Breakdown of academic impact, for papers by Miguel A. Serra Breakdown of academic impact, for papers by Thomas Marjot Breakdown of academic impact, for papers by Christos Tikellis